Acticor Biotech SAS announced the appointment of Patricia Zilliox as an independent director to replace Corinne Le Goff, whose plurality of Board of Directors' seats in the United States no longer allow her to fulfill her mission at Acticor Biotech. The Board of Directors of Acticor Biotech met on January 26, 2023, and co-opted Patricia Zilliox for a three-year term of office, effective immediately. This appointment as an independent member of the Board of Directors will be submitted for ratification at the next Annual General Meeting of Shareholders on May 12, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.92 EUR | -1.08% | +9.52% | -68.28% |
05-15 | Acticor: 'new perspectives' in stroke treatment | CF |
05-15 | Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-68.28% | 13.27M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- ALACT Stock
- News Acticor Biotech SAS
- Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director